MDEA: Difference between revisions

MDEA has been shown to act as a [[releasing agent]] and [[reuptake inhibitor]] of the key [[monoamine]] [[neurotransmitters]] [[serotonin]], [[dopamine]] and [[noradrenaline]]<ref name="MDEApharm" /> which are the [[neurotransmitters]] responsible for modulating focus, motivation, pleasure, and reward. This is done by inhibiting the reuptake and reabsorption of [[monoamine neurotransmitters]] after they have performed their function of transmitting a neural impulse, allowing them to accumulate in the [[synaptic cleft]] and be reused in a manner which causes physically stimulating, sedating, disinhibiting and euphoric effects.<ref>New Insights into the Mechanism of Action of Amphetamines | http://www.annualreviews.org/doi/abs/10.1146/annurev.pharmtox.47.120505.105140</ref> The often-reported "stoning" effects have been theorized to arise from the higher relative activity MDEA has on releasing serotonin over dopamine compared to MDMA.

It has also been noted that MDEA, even at lower doses, stimulates the release of oxytocin and prolactin, two hormones that are currently being studied for their potential roles in modulating the feeling of trust and love.<ref> Passie, Torsten, MD. Healing with Entactogens. Santa Cruz: Multidisciplinary Association for Psychedelic Studies, n.d. Print. </ref>